human | Q5 |
P496 | ORCID iD | 0000-0002-4742-0446 |
P106 | occupation | researcher | Q1650915 |
Q40074608 | A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication |
Q96429221 | Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer |
Q91424068 | Clinical impact of Epstein-Barr virus status on the incidence of lymph node metastasis in early gastric cancer |
Q64938836 | Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. |
Q61455455 | Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer |
Q57453268 | Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer |
Q64066848 | Clinical utility of circulating tumor DNA for colorectal cancer |
Q93362720 | Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer |
Q104515291 | Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy |
Q92961241 | Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer |
Q89122613 | Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer |
Search more.